Adage Capital Partners’s Climb Bio CLYM Stock Holding History
Bought
Maintained
Sold
Other funds holding CLYM
Adage Capital Partners's CLYM Position: Q3 2026 in Review
Adage Capital Partners reduced its Climb Bio (CLYM) stake by 14% in Q3 2026, selling an estimated $4.72M and leaving 2,167,018 shares worth $24.9M. The position accounts for 0.03% of the portfolio, ranked #429.
Adage Capital Partners first reported a position in CLYM in Q2 2024 and has held it in 3 quarters since. The position peaked at $32.7M in Q2 2026. 128 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.
- Adage Capital Partners held 2,167,018 shares of Climb Bio worth $24.9M as of Q3 2026.
- Adage Capital Partners sold 338,982 Climb Bio shares in Q3 2026, an estimated $4.72M.
- Climb Bio made up 0.03% of Adage Capital Partners's portfolio in Q3 2026, its #429 holding.
- Adage Capital Partners first reported a position in Climb Bio in Q2 2024 and has held it in 3 quarters since.
- Adage Capital Partners's Climb Bio position peaked at $32.7M in Q2 2026.
- 128 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.
Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.